icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
xpGnArrR9P4bVQav
Listen
